Molecule
Triclabendazole is an anthelmintic indicated for the treatment of fascioliasis in patients 6 years of age and older. It is available as tablets for oral use. MedsAcross supplies Triclabendazole for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
EGATEN ® is indicated for the treatment of fascioliasis in patients 6 years of age and older. EGATEN ® tablet is an anthelmintic indicated for the treatment of fascioliasis in patients 6 years of age and older.
Source: US FDA prescribing information
Triclabendazole is an anthelmintic against Fasciola species.
Source: US FDA prescribing information
The recommended dose of EGATEN is 2 doses of 10 mg/kg given 12 hours apart in patients 6 years of age and older. The 250 mg tablets are functionally scored and divisible into two equal halves of 125 mg. If the dosage cannot be adjusted exactly, round the dose upwards. Take EGATEN orally with food. EGATEN tablets can be swallowed whole or divided in half and taken with water or crushed and administered with applesauce. The crushed tablet mixed with applesauce is stable for up to 4 hours. Take orally with food. Swallow tablets whole or divide in half and take with water, or crush and administer with applesauce. If the dosage cannot be adjusted exactly, round dose upwards.
Source: US FDA prescribing information
EGATEN is contraindicated in patients with known hypersensitivity to triclabendazole and/or to other benzimidazole derivatives or to any of the excipients in EGATEN. Patients with known hypersensitivity to triclabendazole, other benzimidazole derivatives or any of the excipients in EGATEN.
Source: US FDA prescribing information
QT Prolongation: Prolongs QTc interval. Monitor electrocardiogram (ECG) in patients with a history of QTc prolongation or with electrolyte imbalance like hypokalemia or who are taking medications which prolong the QTc interval, or on CYP1A2 inhibitors, or have hepatic impairment.
Source: US FDA prescribing information
Most common adverse reactions (greater than 2%) with triclabendazole 20 mg/kg dose are abdominal pain, hyperhidrosis, nausea, decreased appetite, headache, urticaria, diarrhea, vomiting, musculoskeletal chest pain, and pruritus.
Source: US FDA prescribing information
CYP2C19 Substrates: Re-check the plasma concentration of concomitantly administered CYP2C19 substrates after cessation of EGATEN therapy, if the plasma concentrations of the CYP2C19 substrates are elevated during administration of EGATEN.
Source: US FDA prescribing information
Store below 30°C (86°F). Storage Store in the original container.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Triclabendazole, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Egaten 250 mg tabletOral | Novartis Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 13 February 2019 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Triclabendazole in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Triclabendazole and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Triclabendazole, including Egaten.
Yes. The US FDA first approved Triclabendazole on 13 February 2019, according to Drugs@FDA.
No listed presentation of Triclabendazole is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Triclabendazole is classified under ATC code P02BX04 (Triclabendazole).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.